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Abstract
Trio exome sequencing has been successful in identifying genes with de novo mutations
(DNMs) causing epileptic encephalopathy (EE) and other neurodevelopmental disorders.
Here, we evaluate how well a case-control collapsing analysis recovers genes causing dom-
inant forms of EE originally implicated by DNM analysis. We performed a genome-wide
search for an enrichment of "qualifying variants" in protein-coding genes in 488 unrelated
cases compared to 12,151 unrelated controls. These "qualifying variants" were selected to
be extremely rare variants predicted to functionally impact the protein to enrich for likely
pathogenic variants. Despite modest sample size, three known EE genes (KCNT1, SCN2A,
and STXBP1) achieved genome-wide significance (p<2.68×10−6). In addition, six of the
10 most significantly associated genes are known EE genes, and the majority of the known
EE genes (17 out of 25) originally implicated in trio sequencing are nominally significant
(p<0.05), a proportion significantly higher than the expected (Fisher’s exact p = 2.33×10−17).
Our results indicate that a case-control collapsing analysis can identify several of the EE
genes originally implicated in trio sequencing studies, and clearly show that additional
genes would be implicated with larger sample sizes. The case-control analysis not only
makes discovery easier and more economical in early onset disorders, particularly when
large cohorts are available, but also supports the use of this approach to identify genes in
diseases that present later in life when parents are not readily available.
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Author summary
Trio exome sequencing and de novo mutation (DNM) analysis has been the main
approach to discovering genes responsible for severe sporadic disorders, including a
range of neurodevelopmental disorders. This approach requires sequencing parents, iden-
tifying DNMs from trio sequence data, and comparing the observed rate of DNMs to the
expected. In this study, we adopted a case-control design, performed a gene-based collaps-
ing analysis, and rediscovered several of the epileptic encephalopathy (EE) genes originally
implicated by DNM analysis of EE trios. Our collapsing analysis focused on ultra-rare,
highly impactful variants (“qualifying variants”) by filtering against large-scale population
datasets, and this approach revealed that most of the standing variation can be filtered out
and DNMs are enriched in “qualifying variants”. Our study suggests that a case-control
analysis approach can be used to identify disease genes with causal mutations that are pre-
dominantly de novo in place of trio-based analysis methods. This offers an efficient and
cost effective alternative approach when large-scale trio sequencing is not possible.
Introduction
One of the most important recent developments in human genomics is the use of a trio
sequencing paradigm to implicate new disease genes in sporadic disease by evaluating patterns
of de novo mutations (DNMs). This framework compares the observed pattern of DNMs in
probands to the expected based on the size of the protein-coding sequence and the estimated
tri-nucleotide mutation rate[1], and has implicated scores of genes conferring risk of epilepsy
[2, 3], intellectual disability[4–6], autism[7–10], and other neurodevelopmental conditions[4].
This approach is costly because of the need to sequence complete trios and often is not practi-
cal or possible for conditions that present after childhood where parents may not be available
for sequencing. Moreover, a precise estimate of mutation rate is not available for small inser-
tion/deletions (indels)[1], limiting the ability to assess the significance of genes harboring de
novo indels.
In parallel to these developments, collapsing analyses, which typically compare the burden
of rare, presumably deleterious variants gene by gene in cases versus controls, have proven
increasingly successful in implicating diseases genes, for example in amyotrophic lateral scle-
rosis[11, 12], idiopathic pulmonary fibrosis[13, 14], and monogenic disorders[15]. Surpris-
ingly, however, it has not yet been assessed whether the collapsing framework can identify the
genes implicated by analysis of trio sequencing data. We addressed this question by imple-
menting a genome-wide gene-based collapsing analysis using whole exome sequencing (WES)
data generated from 488 epileptic encephalopathy (EE) patients, including those previously
analyzed using the trio-based DNM analysis framework, and a large cohort of unrelated con-
trol individuals to assess the efficacy of case-control analysis to identify disease genes impli-
cated by DNM analysis for EE. Strikingly, despite a modest sample size, we identified three
known EE genes achieving genome-wide significance (p<2.68×10−6), and found that the
majority of the known EE genes (17 out of 25) originally implicated in trio sequencing are
nominally significant (p<0.05). While not all known EE genes reached genome-wide signifi-
cance, the significant enrichment of known genes among nominally significant p-values
genome-wide suggests that with larger samples sizes many of these genes will reach p-values
that will exceed that threshold. Collectively, our results show that collapsing analysis can effec-
tively implicate genes carrying causal DNMs, and trio sequencing is not the only effective
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strategy for gene discovery even in genes that confer risk largely due to DNMs. We argue that
the fundamental reason for this is that existing filtering strategies are increasingly accurate in
identifying very young mutations including those that are de novo in the proband.
Results and discussion
The collapsing analysis compared a total of 488 cases with 12,151 controls (S1 Fig). Three
genes (Fig 1, Table 1, S1 Table, and S2 Fig), KCNT1, SCN2A and STXBP1, showed enrichment
of qualifying variants in EE patients and achieved genome-wide significance (p<2.68×10−6).
No other genes were found to be genome-wide significant by both Fisher’s exact test and logis-
tic regression p-values, but 17 of the 25 genes (68%, including the three above) known to be
associated with dominant EE (https://www.omim.org/phenotypicSeries/PS308350) were
nominally significant (logistic regression p<0.05) in this dataset, all showing enrichment of
qualifying variants in EE patients (Table 1). This is in contrast to the total of 885 nominally sig-
nificant (logistic regression p<0.05) genes out of all the 18,503 genes tested (Fisher’s exact
p = 2.33×10−17). We used a hypergeometric test to assess whether these 25 known dominant
EE genes tend to have lower p-values in our case-control gene-based collapsing analysis com-
pared with the rest of the genome. Specifically, at each observed ranking of the 25 epilepsy
genes (based on logistic regression p-values), we performed a hypergeometric test to assess
whether there were more epilepsy genes at this ranking, or lower, than one would expect if the
ranks were randomly assigned to all 18,503 genes tested (Table 1). There was a consistent pat-
tern that known dominant EE genes tended to have smaller p-values in our dataset (Table 1).
In the 25 genes known to cause dominant forms of EE, 74 of the 488 cases (15.16%) had at
least one qualifying variant, compared to 302 of the 12,151 controls (2.49%, Fisher’s exact
p = 1.95×10−32). Among the 64 of the 74 cases with trio WES data, a total of 73 qualifying vari-
ants were found in these 25 EE genes, and 47 of these qualifying variants (64.4%) were con-
firmed to be de novo in our previous DNM analyses (Table 1 and S2 Table), including all the
qualifying variants in STXBP1 (n = 6), DNM1 (n = 5), KCNQ2 (n = 3), GNAO1 (n = 2), CDKL5
(n = 3), ALG13 (n = 1) and SLC35A2 (n = 1) identified in the 488 cases (no inherited qualifying
variant was observed in these genes in all cases; Table 1).
Comparing 488 EE cases and 12,151 controls using a gene-based collapsing analysis of
“qualifying variants”, we successfully identified three known EE genes at genome-wide signifi-
cance level. In addition, known EE genes were found to have smaller than expected association
p-values compared with the rest of the genome. We showed that DNMs contributed to the
majority of qualifying variants in the 25 known dominant EE genes identified in cases, and in
several genes they accounted for all of them. As most of these 25 EE genes are originally impli-
cated by sequencing trios and analyzing DNMs, our results clearly demonstrate the efficacy of
case-control gene-based collapsing analysis to identify genes without spending effort specifi-
cally ascertaining DNMs by sequencing trios.
Several factors affect the power of case-control gene-based collapsing analysis, including
locus heterogeneity, penetrance, and how “qualifying variants” are defined as a class to repre-
sent the properties of bona fide pathogenic mutations. Because most if not all known EE-caus-
ing mutations are not observed in ExAC, we required the qualifying variants to be absent in
ExAC. Remarkably, because of the large sample size of ExAC, most standing variation is essen-
tially filtered out (except mutations arising in recent generations, including DNMs), and
indeed 64.4% of the qualifying variants in the 25 known EE genes are confirmed to be de novo
in 64 cases, thus recovering many of the EE genes originally implicated by DNM analysis.
Notably, all the six STXBP1 and five DNM1 qualifying variants in cases are de novo, highlight-
ing the power of using ExAC to filter out standing variation. However, even at the sample size
Collapsing analysis of epileptic encephalopathies
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of ExAC, where widespread mutational recurrence is observed[16], background variation in
controls may still prevent a gene that is securely implicated in DNM analysis from reaching
genome-wide significance in case-control analysis. For example, in DNM1, even with five qual-
ifying variants (all DNMs) in unrelated cases, there are 18 qualifying variants in controls unfil-
tered by ExAC. These 18 qualifying variants may be private but not DNMs, and may be
further filtered out by a larger and more genetically diverse control datasets. Indeed, although
most genes known to cause EE (and other neurodevelopmental disorders) are intolerant to
standing functional variation[17], implying a lower rate of background variation than the
genomic average, our empirical data shows considerable variability in the frequency of qualify-
ing controls across the 25 EE genes (Table 1). Versions of collapsing that focus on subregions
of genes will likely allow finer discriminations amongst pathogenic variants and background
variation.
As a class, disease-causing DNMs clearly represent the extreme of rare variation by typically
not being able to pass even one generation due to extremely strong negative selection. How-
ever, this does not mean every DNM identified in an individual is pathogenic, and there are
DNMs presenting as standing variation in human population datasets like ExAC and these
DNMs are unlikely to be pathogenic[18]. By focusing on qualifying variants absent in ExAC,
Fig 1. A. Quantile-quantile (QQ) plot for genome-wide gene-based collapsing analysis. The Y-axis
represents -log10 of observed (red) p-values (sorted) evaluated in the logistic regression adjusting for the total
number of “ultra-rare” synonymous variants per individual; the X-axis represents -log10 of expected p-values
(sorted) evaluated in the same logistic regression model with permutation (“BiasedUrn”). The dashed grey
lines indicate permutation-based 95% confidence intervals.
https://doi.org/10.1371/journal.pgen.1007104.g001
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such presumably benign DNMs can be excluded from collapsing analysis. Conversely, if a
pathogenic variant is inherited and the parent is not known to be affected (e.g., due to incom-
plete penetrance or variable phenotype), it would not be identified in trio-based analyses
focused on DNMs but may be captured in case-control analyses.
The DNM analysis framework typically compares observed rate of DNMs in cases with
expectation relying on estimates of the mutability of genes since very large populations of con-
trol trios are not available for direct comparisons. Precisely estimating mutation rate across the
human genome is difficult and the current DNM analysis framework cannot effectively
Table 1. Association results for the 25 genes known to cause dominant forms of epileptic encephalopathy.
Logistic
P Rank
Gene Case
(Trios)c
Case
Frequency
Controld Control
Frequency
Collapsing
Logistic Pe
Collapsing
Fisher’s
Exact P
Probability of seeing
this many (or more)
known epilepsy
genes at this rankingf
Case
de
novog
Case
inheritedg
1 KCNT1a 10 (4) 0.0205 14 0.0012 2.53E-09 8.1E-09 1.35E-03 2h 1h
2 STXBP1a 6 (6) 0.0123 4 0.0003 1.37E-07 5.9E-07 1.75E-06 6 0
3 SCN2Aa 8 (7) 0.0164 14 0.0012 2.82E-07 9.3E-07 2.18E-09 4 3
6 SCN8Ab 8 (8) 0.0164 26 0.0021 1.37E-05 3.5E-05 3.88E-11 4 4
8 GABRB3b 3 (2) 0.0061 2 0.0002 1.30E-04 0.00054 1.64E-13 2 0
9 SCN1Ab 8 (8) 0.0164 36 0.0030 1.38E-04 0.00024 2.66E-16 7 1
14 GRIN2Bb 5 (5) 0.0102 16 0.0013 3.83E-04 0.001 1.11E-17 2 3
18 GABRA1b 3 (3) 0.0061 4 0.0003 4.62E-04 0.0018 1.38E-19 2 1
23 DNM1b 5 (5) 0.0102 18 0.0015 6.65E-04 0.0016 2.36E-21 5 0
41 KCNQ2b 3 (3) 0.0061 6 0.0005 1.13E-03 0.004 2.77E-21 3 0
42 SPTAN1b 7 (7) 0.0143 40 0.0033 1.15E-03 0.002 8.59E-24 1 6
136 HCN1b 2 (1) 0.0041 4 0.0003 6.43E-03 0.0201 7.26E-20 0 1
317 ALG13b 1 (1) 0.0020 1 0.0001 0.017 0.0757 3.71E-17 1 0
353 GABRB1b 2 (2) 0.0041 7 0.0006 0.019 0.0447 2.41E-18 1 1
402 GNAO1b 2 (2) 0.0041 9 0.0007 0.023 0.065 2.35E-19 2 0
409 CDKL5b 3 (3) 0.0061 17 0.0014 0.023 0.04 4.14E-21 3 0
737 SLC35A2b 1 (1) 0.0020 3 0.0002 0.045 0.1457 1.07E-18 1 0
1411 SIK1 1 (0) 0.0020 5 0.0004 0.086 0.2105 1.97E-15 N/A N/A
1944 GRIN2D 1 (1) 0.0020 7 0.0006 0.124 0.2703 2.24E-14 0 1
3232 KCNB1 1 (1) 0.0020 11 0.0009 0.228 0.3767 1.43E-11 0h 0h
3732 CACNA1A 2 (2) 0.0041 28 0.0023 0.277 0.3234 1.29E-11 1 1
3755 PCDH19 1 (1) 0.0020 13 0.0011 0.280 0.4239 6.65E-13 0 1
6110 EEF1A2 0 (0) 0 3 2.47E-04 0.453 1 1.17E-09 N/A N/A
11309 KCNA2 0 (0) 0 7 5.76E-04 0.730 1 7.57E-05 N/A N/A
13606 SLC1A2 0 (0) 0 10 8.23E-04 0.847 1 4.57E-04 N/A N/A
a Genome-wide significant (both logistic regression and Fisher’s exact p-values <2.68×10−6).
b Nominally significant (logistic regression p-value <0.05).
c Number of cases carrying at least one qualifying variant in the gene (number of complete trios sequenced).
d Number of controls carrying at least one qualifying variant in the gene.
e Adjusted for the total number of "ultra-rare" synonymous variants per individual (see Methods).
f Probabilty of observing x, or more, known epilepsy genes at ranking r if one were to randomly draw r genes at random from a collection of 18,503 genes
with 25 being known epilepsy genes. Calculation by upper tail of hypergeometric distribution characterizing sampling without replacement from a collection
25 known epilepsy genes and 18,478 non-epilepsy genes.
g In cases with trio WES data.
h One trio without DNA available for all three for Sanger validation.
https://doi.org/10.1371/journal.pgen.1007104.t001
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accommodate indels well due to lack of accurate estimations of mutation rate for this class of
variants. However, case-control analysis directly compares the pattern of qualifying variants
empirically observed in both cases and controls and is not affected by mutation rate estimates.
When a disease gene is securely implicated using a case-control framework, caution is
needed to interpret the causality of qualifying variants identified in that gene. Importantly, an
excess of qualifying variants in cases versus controls does not imply all qualifying variants in
cases are pathogenic or all qualifying variants in controls are benign. Instead, interpretation
should be performed per variant per individual after the case-control association testing is per-
formed. Certainly, for an individual case, knowledge of whether a variant is de novo or not
remains an important consideration in diagnostic interpretation[19]. However, our work
clearly shows that a collapsing analysis using only probands can also discover genes that cause
disease due to DNMs. This not only makes discovery easier and more economical in early
onset disorders, but opens up the possibility of identifying genes that carry causal DNMs in
diseases that present later in life when parents are not readily available. These results have clear
implications for discovery strategies in a range of different genetic diseases.
Materials and methods
Subjects and sequencing
We started with WES or whole genome sequencing (WGS) data generated from 496 cases
selected from several genetic studies of EE and 12,916 controls selected from other studies and
not known to have neurodevelopmental, neuropsychiatric, or severe pediatric diseases. The cases
were originally recruited and studied by groups including the Epi4K Consortium, the Epilepsy
Phenome Genome Project (EPGP), the Epilepsy Genetics Initiative (EGI)—a signature program
of Citizens United for Research in Epilepsy (CURE), and EuroEPINOMICS-RES Consortium.
Written informed consent was collected at the time of recruitment at each of the clinical
sites. Patient collection and sharing of anonymized specimens for research was approved by
site-specific Institutional Review Boards and ethic committees. Details of the IRB and approval
numbers are available from S3 Table.
To maximize sample size, both cases and controls included individuals with diverse ances-
tries including African, Caucasian, East Asian, Hispanic, Middle Eastern, and South Asian.
After relatedness check and principal component analysis, a total of 488 cases and 12,151 con-
trols remained for association analysis, and 75.6% of cases (n = 369, S4 Table) had been ana-
lyzed previously in trio or single-patient interpretation analyses.
Sequencing was performed at multiple sites (S2 Table). All data starting from either FASTQ
or BAM files were processed through the alignment and annotation pipeline at the Institute
for Genomic Medicine at Columbia University Medical Center (formerly Center for Human
Genome Variation at Duke University). Case (S2 Table) and control samples were sequenced
after exome capture using a variety of technologies (Agilent Clinical Research Exome, IDT
xGen Exome Research Panel V1.0, Illumina Nextera Rapid Capture—Expanded Exome
[62MB], SeqCap EZ Exome v2, SeqCap EZ Exome v3, SeqCap EZ MedExome, SureSelect
Human All Exon - 50MB, SureSelect Human All Exon - 65MB, SureSelect Human All Exon
V4, SureSelect Human All Exon V4 - 50MB, SureSelect Human All Exon V4 + UTR, SureSe-
lect Human All Exon V5, SureSelect Human All Exon V5 + UTR, and VCRome2_1) or whole
genome sequenced according to standard protocols.
IGM bioinformatics pipeline
After quality filtering the raw sequence data using CASAVA (Illumina, Inc., San Diego, CA),
the Illumina lane-level FASTQ files were aligned to the Human Reference Genome (NCBI
Collapsing analysis of epileptic encephalopathies
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Build37/hg19) using the Burrows-Wheeler Alignment Tool (BWA).[20] Picard (http://picard.
sourceforge.net) was used to remove duplicate reads and process these lane-level SAM files,
resulting in a sample-level BAM file that was used for variant calling. Variant and genotype
calling was performed using the GATK software with local re-alignment around insertion/
deletion variants and base quality recalibration for variants[21].
Variants for analysis were restricted to the consensus coding sequence public transcripts
(CCDS release 14) plus 2 base pair intronic extensions[22]. Variants were further required to
have: i) at least 10-fold coverage, ii) quality score (QUAL) of at least 30, iii) genotype quality
(GQ) score of at least 20, iv) quality by depth (QD) score of at least 2, v) mapping quality (MQ)
score of at least 40, vi) read position rank sum (RPRS) score greater than -3, vii) mapping qual-
ity rank sum (MQRS) score greater than -6, viii) indels were required to have a maximum
Fisher’s strand bias (FS) of 200, ix) variants were screened according to VQSR tranche calcu-
lated using the known SNV sites from HapMap v3.3, dbSNP, and the Omni chip array from
the 1000 Genomes Project to “PASS” SNVs were required to achieve a tranche of 99.9% for
SNVs in genomes and exomes and 99% for indels in genomes, x) for heterozygous genotypes,
the alternate allele ratio was required to be25%. Finally, variants were excluded if they were
among a predefined list of known sequencing artifacts or if they were marked by EVS (http://
evs.gs.washington.edu/EVS/)[23] or ExAC (http://exac.broadinstitute.org/about)[16] as being
problematic variants. Variants were annotated to Ensembl 73[24] using SnpEff[25].
Quality control, relatedness check and principal component analysis
Any exomes with gender discordance between clinically-reported and X:Y coverage ratios
were removed, as were contaminated samples according to VerifyBamID[26].
Before running gene-based collapsing analysis, we implemented both sample- and site-level
pruning procedures to minimize the systemic bias in data that might lead to spurious associa-
tion or reduced power to detect real association. The site-pruning procedure (coverage harmo-
nization) is described in the section below. Here, we described the sample-level pruning
procedure including removing related individuals and population outliers identified in princi-
pal component analysis (PCA).
To identify related individuals, we generated genotype data in PLINK format[27] and then
used KING[28] to calculate pairwise kinship coefficients for all case and control subjects. We
used the kinship coefficient 0.1 as a cutoff and removed samples introducing relatedness while
preferentially retaining cases; we retained samples with a higher overall coverage in the CCDS
regions to break ties if applicable. After this step, 492 of the 496 cases and 12,248 of the 12,916
controls were kept for further analysis.
Next we ran PCA using EIGENSTRAT[29] on the 492 cases and 12,248 controls with a LD-
pruned (r2 threshold 0.1) list of single-nucleotide polymorphisms (SNPs) extracted from exo-
mic sequencing data. After removing outliers given a sigma threshold (6.0 along the top10
principal components) for 5 iterations, a total of 488 cases and 12,151 controls entered gene-
based collapsing analysis (S1 Fig).
Coverage harmonization (site-pruning)
For the 488 cases and 12,151 controls entering association analysis, at least 10-fold coverage
was achieved for an average of 93.20% in cases and 95.19% in controls of the 33.27 MB of the
consensus coding sequence (CCDS release 14) plus 2 base pair (bp) intronic extensions (to
accommodate canonical splice site variants). To address the confounding effect introduced by
imbalance of coverage between cases and controls, we pruned out sites with uneven coverage
in cases and controls using our previously described site-pruning procedure[30]. Specifically,
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for each site in CCDS plus 2 bp extensions, we determined the percentages of cases and con-
trols that had at least 10-fold coverage, and that site was excluded from further analysis if the
percentages differed by >11.97% between cases and controls. This site-pruning procedure
removed 8.58% of the CCDS (+2bp intronic extensions) bases from the analysis. After site
pruning, at least 10-fold coverage was achieved for an average of 88.27% in cases and 88.12%
in controls of the 33.27 MB CCDS (+2bp intronic extensions) bases. These sites entered the
association analysis where case and control populations had a comparable coverage to accu-
rately compare patterns of variation gene by gene.
Collapsing analysis
To identify genes associated with EE under the case-control association analysis framework,
we performed a genome-wide search for an enrichment of “qualifying variants” in protein-
coding genes in cases compared to controls looking for risk alleles. A “qualifying variant” was
determined by a set of criteria, based on allele frequency and functional predictions, designed
to capture the characteristics of pathogenic variants associated with EE. Specifically, in this
study, we focused on “ultra-rare”, highly impactful variants, and a variant was determined to
be qualifying if it: 1) was absent in the Exome Variant Server (EVS) and Exome Aggregate
Consortium (ExAC release 0.3); 2) had4 copies of variant allele in the 488 cases plus 12,151
controls; and 3) was predicted to be loss-of-function (stop_gained, frame_shift, splice_site_ac-
ceptor, splice_site_donor, start_lost, or exon_deleted) or missense “probably damaging” by
PolyPhen-2 (HumDiv). We focused on this subset in an effort to try to capture the de novo var-
iant signal that has been previously reported to play a role in a range of epilepsies and in partic-
ular EE subtypes [2, 31, 32]. For each gene, an indicator variable (1/0 states) was assigned to
each individual based on the presence of at least one qualifying variant in the gene (state 1) or
no qualifying variant in that gene (state 0); this was equivalent to a dominant genetic model.
Accordingly, for a given gene, a qualifying case (or control) was defined to be a case (or con-
trol) subject carrying at least one qualifying variant in that gene. We used two-tailed Fisher’s
exact test to evaluate statistical significance of genic association. To address the potential con-
founding effect of background rate of “qualifying variants,” we further constructed a logistic
regression model including the total number of “ultra-rare” (absent in EVS and ExAC and
having4 copies of variant allele in the 488 cases plus 12,151 controls) synonymous variants
per individual as covariate. To account for bias due to small counts of qualifying variant, we
employed a Firth correction with profile likelihood based tests [33, 34]. With 18,668 CCDS
genes we aimed to test, we adopted the genome-wide significance level of p = 2.68×10−6 using
Bonferroni correction (0.05/18,668).
Quantile-quantile probability plots and genomic inflation factor (λ)
Quantile-quantile plots were generated using a permutation-based expected probabilities dis-
tribution. To achieve this, for each model (matrix) we randomly permuted the case and control
labels of the original configuration: 488 cases and 12,151 controls and then recomputed the
Fisher’s Exact test for all genes. This was repeated 1,000 times. For each of the 1,000 permuta-
tions we ordered the p-values and then took the mean of each rank-ordered estimate across
the 1,000 permutations, i.e., the average 1st order statistic, the average 2nd order statistic, etc.
These then represent the empirical estimates of the expected ordered p-values (expected
-log10(p-values)). This empirical-based expected p-value distribution no longer depends on
an assumption that the p-values are uniformly distributed under the null. For comparison we
have provide QQ plots for the actual p-values (S2 Fig) and empirically-based expected p-value
distribution (S3 Fig).
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To compute the permutation-based expected p-value distribution for Firth logistic regres-
sion, due to the presence of the covariate (the total number of “ultra-rare” synonymous vari-
ants per individual), we implemented permutation using the R package “BiasedUrn” (https://
cran.r-project.org/web/packages/BiasedUrn/) to maintain the confounding role of covariate in
each permuted data set while the association between genotype and disease was broken[35].
Permutation was performed 1,000 times and the empirical-based expected p-value distribution
was calculated in the same way as described above. For comparison to the BiasedUrn per-
muted p-values, we have provided QQ plots for the actual p-values generated from the Firth
logistic regression (S4 Fig).
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